RTP Mobile Logo
Hematologic Oncology Update, Issue 4, 2011
Released January 2012

Featuring interviews with Drs Ruben A Mesa, Robert Z Orlowski, Myron S Czuczman and Moshe Talpaz. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES 

    • Use case-based learning to formulate individualized strategies for the care of patients with hematologic cancer.
    • Develop an evidence-based treatment approach for younger and older patients with mantle-cell lymphoma.
    • Counsel patients with follicular lymphoma about recent advances in induction and maintenance systemic treatment.
    • Summarize the critical factors in selecting patients with chronic myelogenous leukemia for treatment with first- and second-generation tyrosine kinase inhibitors.
    • Employ an understanding of recent findings with proteasome inhibitors and immunomodulatory agents in individualized induction and maintenance therapy for patients with multiple myeloma.
    • Develop an understanding of the mechanisms of action and the emerging efficacy and side-effect data with JAK2 inhibitors in myelofibrosis in order to inform future patients about protocol and nonprotocol options.
    • Facilitate patient access to clinical trial participation through communication of ongoing research opportunities.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Mesa had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr OrlowskiAdvisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Paid Research: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr CzuczmanAdvisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Onyx Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc; Lecture: Celgene Corporation, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Mundipharma International Limited; Paid Research: Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation. Dr TalpazAdvisory Committee: Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi.


    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This enduring material contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi and Seattle Genetics.


    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2012
    Expiration date: January 2013

Acknowledge and close

Listen to audio:
Hematologic Oncology Update, Issue 4, 2011
Released January 2012

Featuring interviews with Drs Ruben A Mesa, Robert Z Orlowski, Myron S Czuczman and Moshe Talpaz. (Text and Audio Content)

Read print: